|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||85.38 - 86.66|
|52-week range||55.06 - 89.69|
|PE ratio (TTM)||21.24|
|Dividend & yield||2.56 (2.93%)|
|1y target est||N/A|
Roche Holdings AG (RHHBY) announced positive results from the phase III study, MURANO on leukemia drug Venclexta.
A bank, a tech company, and a huge pharmaceutical player are all still buys.
On the hunt for a fat dividend yield? These three big pharma stocks deliver.